[Factors of resistance of ovarian cancer to combined chemotherapy with the use of platinum derivatives].
Bliumenberg
A G
AG
Gorbacheva
L B
LB
Gorbunova
V A
VA
Kozachenko
V P
VP
Lankin
V Z
VZ
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D018269:Carcinoma, Endometrioid / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D019008:Drug Resistance, Neoplasm; D005260:Female; D005978:Glutathione / Q000378:metabolism; D005979:Glutathione Peroxidase / Q000378:metabolism; D005982:Glutathione Transferase / Q000378:metabolism; D006801:Humans; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011379:Prognosis
D014408:Biomarkers, Tumor; D009944:Organoplatinum Compounds; D005979:Glutathione Peroxidase; D005982:Glutathione Transferase; D005978:Glutathione